Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ENABLE Study: An Open-Label, Long-Term Safety and Efficacy Study of INZ-701 in Patients With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency

NCT06739980 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT06739980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06739980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ENABLE Study: An Open-Label, Long-Term Safety and Efficacy Study of INZ-701 in Patients With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency
Lead sponsor
Inozyme Pharma
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2025
Completion date
March 31, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal recessive hypophosphatemic rickets, ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency, generalized arterial calcification of infancy 1